Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Roche Holding AG    ROG   CH0012032048

ROCHE HOLDING AG

(ROG)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Swiss Exchange
09/14/2020 09/15/2020 09/16/2020 09/17/2020 09/18/2020 Date
330(c) 335.45(c) 337.15(c) 336.9(c) 343.1(c) Last
1 655 648 1 654 217 1 752 424 1 730 931 4 506 337 Volume
+0.20% +1.65% +0.51% -0.07% +1.84% Change
More quotes
Financials
Sales 2020 61 405 M 67 355 M 67 355 M
Net income 2020 15 030 M 16 487 M 16 487 M
Net cash position 2020 3 301 M 3 621 M 3 621 M
P/E ratio 2020 20,1x
Yield 2020 2,72%
Sales 2021 63 555 M 69 714 M 69 714 M
Net income 2021 16 062 M 17 618 M 17 618 M
Net cash position 2021 11 933 M 13 090 M 13 090 M
P/E ratio 2021 18,7x
Yield 2021 2,82%
Capitalization 293 B 322 B 321 B
EV / Sales 2020 4,72x
EV / Sales 2021 4,42x
Nbr of Employees 97 735
Free-Float 83,6%
More Financials
Company
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The... 
Sector
Pharmaceuticals
Calendar
09/23 | 03:50amPresentation
More about the company
Notations Surperformance© of Roche Holding AG
Trading Rating : Investor Rating :
More Ratings
All news about ROCHE HOLDING AG
09/19ROCHE : presents new data from multiple Phase III studies of Tecentriq in triple..
PU
09/19ROCHE : presents new data from multiple Phase III studies of Tecentriq in triple..
AQ
09/19GENENTECH : Presents New Data From Multiple Phase III Studies of Tecentriq in Tr..
BU
09/19Roche presents new data from multiple Phase III studies of Tecentriq in tripl..
GL
09/18ROCHE : rises on word of COVID trial win, new test and European cancer drug nod
RE
09/18ROCHE : receives positive CHMP opinion for Tecentriq in combination with Avastin..
AQ
09/18ROCHE : receives positive CHMP opinion for Tecentriq in combination with Avastin..
PU
09/18ROCHE : receives positive CHMP opinion for Tecentriq in combination with Avastin..
AQ
09/18Roche receives positive CHMP opinion for Tecentriq in combination with Avasti..
GL
09/18HALOZYME THERAPEUTICS : Announces Poster Presentation Of Data from Roche's Phase..
AQ
09/18CORVUS PHARMACEUTICALS : New Data from Ciforadenant Phase 1b/2 Clinical Study Pr..
AQ
09/18ROCHE : Arthritis Drug Meets Key Endpoint in Covid-19 Pneumonia Study
DJ
09/18ROCHE HOLDINGS AG : Receives a Buy rating from UBS
MD
09/18ROCHE : phase III EMPACTA study showed Actemra/RoActemra reduced the likelihood ..
AQ
09/18ROCHE : Launches Quantitative Test for Coronavirus Antibodies
DJ
More news
News in other languages on ROCHE HOLDING AG
09:12aRoche présente diverses données sur Tecentriq lors du congrès ESMO
08:49aRoche präsentiert an ESMO verschiedene Daten zu Tecentriq
09/18ROCHE : avis positif du CHMP sur Tecentriq
09/18ROCHE : avis favorable du CMPH pour Tecentriq/Avastin (cancer du foie)
09/18Roche erhält positive Empfehlung der EU für Tecentriq/Avastin gegen Leberkreb..
More news
Analyst Recommendations on ROCHE HOLDING AG
More recommendations
Stock Trading Strategies
ROCHE HOLDING AG - 07/28
Back on an important level
BUY
More Stock Trading Analysis
Chart ROCHE HOLDING AG
Duration : Period :
Roche Holding AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ROCHE HOLDING AG
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 24
Average target price 379,32 CHF
Last Close Price 343,10 CHF
Spread / Highest target 21,5%
Spread / Average Target 10,6%
Spread / Lowest Target -5,28%
EPS Revisions
Managers
NameTitle
Severin Schwan Chief Executive Officer & Executive Director
Christoph Franz Chairman
Alan Hippe Chief Financial & Information Technology Officer
Paul Bulcke Non-Executive Director
André S. Hoffmann Vice Chairman
Sector and Competitors
1st jan.Capitalization (M$)
ROCHE HOLDING AG9.27%322 209
JOHNSON & JOHNSON2.27%392 765
MERCK & CO., INC.-5.65%217 034
PFIZER, INC.-6.02%203 549
NOVARTIS AG-9.76%200 978
NOVO NORDISK A/S12.50%161 415